Precursor Ventures

Precursor Ventures is a team-first pre-seed and seed investor that writes first institutional checks into North American startups, with a broader geographic exception in fintech. The firm is intentionally sector-agnostic across software, hardware, and select consumer businesses, but avoids biotech, life sciences, and later-stage rounds, preferring to back founders before product or revenue exists.

Evaluation weights

How much weight this investor places on each dimension. Totals 100%.

Team-led · 47%

Metrics

Revenue, growth, and unit economics

Market

30%

Size, timing, and competitive landscape

Team

47%

Founder experience and execution ability

Product

18%

Differentiation and technical quality

Strong bias toward founder quality over current traction
Willingness to invest before product, revenue, or clear data exists
Prefers zero-to-one opportunities where first-check investors can matter
Rejects opportunities that fall outside stage, round-size, or sector boundaries

Pitch difficulty

How hard it is to get a meeting and close funding from this investor.

Funded / yr

Deals closed in a typical year.

Led / yr

Rounds led in the last 12 months.

Pitches / yr

~2000

Decks reviewed in a typical year.

Acceptance rate

0.05%

Share of pitches that get funded.

Estimated — public data is not fully disclosed.

Why it's hard

Funds roughly 1% of inbound opportunities
Team bar is exceptionally high because decisions are often made with little data
Only invests at Pre-Seed and Seed, generally in rounds of $5M or less
Explicitly avoids biotech, life sciences, Series A entry, and many capital-intensive models

Precursor is unusually open to pre-traction companies, but it is still extremely selective because it funds only about 1% of 3,000+ annual pitches. Its narrow stage mandate, explicit exclusions, and strong founder bar make getting a yes difficult despite broad sector coverage.

Green flags

What drives a yes for this investor.

Exceptional founder quality despite limited data
A believable path to $100M ARR within roughly seven years
A market the firm does not 'hate' and that can support venture outcomes
Non-obvious advantage in segmentation, business model, or founder insight
Round size, stage, and capital needs that fit Precursor's pre-seed/seed model

Red flags

What kills deals and gets a fast no.

Series A or later-stage fundraising asks
Biotech, life science, or deep-science opportunities outside the firm's expertise
Round sizes or capital requirements that exceed the firm's model
No credible path to venture-scale outcomes
Conflicts with existing portfolio companies

How to win

Patterns that lead to successful pitches.

Lead with founder insight, not just current traction
Show why this team can build a $100M ARR company from a small starting wedge
Frame the opportunity within a pre-seed/seed financing plan that is capital efficient
Demonstrate a market insight or segmentation advantage that others overlook
Make clear why the business is technology-centric even if it touches hardware or consumer

Fund strategy & identity

Who they are and how they operate.

Invests primarily in Pre-Seed and Seed rounds of $5M or less
Typically writes $250K-$500K checks, with ability to lead rounds of $1M or less
Focuses on North America, with a global exception for fintech
Maintains reserves for follow-on support in breakout companies
Avoids Series A entry, biotech, and capital-intensive non-tech businesses

Firm identity

Team-first, people-over-product investor Pre-Seed and Seed specialist First institutional check provider Sector-agnostic across B2B and B2C High-conviction but highly selective early-stage firm

Investment focus

Industries, themes, and typical ARR expectations.

Industries

B2B SaaSB2C softwareFintechMarketplacesAI/ML applicationsConsumer tech and tech-enabled brandsHardware-enabled technology businesses

Investment themes

Founders with unusual insight before traction existsB2B and B2C software platforms with large scaling potentialFintech infrastructure and regulated financial servicesVertical AI and workflow automation in large industriesConsumer brands or hardware with technology-enabled leverageMarketplaces and labor/logistics platforms in overlooked categories

Typical check by stage

Pre Seed$50K-$500K

Seed$250K-$500K

Series A$100K-$500K

Series B$0-$250K

Typical ARR by stage

Pre Seed$0

Seed$0-$1M

Investment thesis

Core beliefs and strategy behind their investing approach.

Precursor Ventures is a pre‑seed and seed‑stage venture firm that invests primarily in North America, with a global exception for fintech. It is sector‑agnostic, allocating roughly half of its capital to B2B and half to B2C software and hardware businesses. The firm explicitly avoids biotech and life‑science companies because it lacks scientific expertise, and it does not enter at Series A or in rounds larger than $5 M. Check sizes are typically up to $500 K per company, with the ability to lead rounds of $1 M or less. Precursor believes that value creation is driven by backing “people over product” – the strongest founders are funded as the first institutional check, allowing the firm to shape the zero‑to‑one journey and provide follow‑on capital. By maintaining reserves for later rounds and staying away from capital‑intensive, non‑technology‑centric businesses, Precursor aims to capture outsized upside from early‑stage companies that can scale to large revenues once the founder’s vision is validated.

Decision patterns

How they evaluate and make investment decisions.

Precursor’s evaluation framework is fundamentally team‑first, followed by market and then product. Internally the firm weights roughly 70 % founder quality and 30 % market attractiveness, requiring the market to be at least “not hated.” Traction is not a prerequisite; the firm often invests in the “no‑data” quadrant where both business and founder information are scarce, giving it a competitive edge. Decision‑makers look for durable, non‑obvious advantages in business model or market segmentation, and they apply a mental scorecard asking if the company could reach $100 M ARR in seven years with healthy margins. Deal‑breakers include conflicts with existing portfolio companies, entry at Series A, and investments in biotech or capital‑intensive businesses without a clear technology angle. Typical deals are pre‑seed or seed rounds ≤$5 M, with initial checks of $250‑$500 K, and the firm keeps reserves for follow‑on support.

Risk appetite

Precursor exhibits an aggressive risk profile for early‑stage investing. It is comfortable being the first institutional investor, often funding teams before any product, revenue, or traction exists. While it can lead rounds up to $1 M, it does not require a lead position, allowing rapid participation when conviction is high. The firm targets founders who could scale to $100 M ARR within seven years, basing the assessment on founder quality rather than current metrics. This high‑risk tolerance is balanced by disciplined selection—only about 1 % of the 3,000+ annual pitches are funded—and by maintaining reserves for follow‑on investments.

Notable investments

Key portfolio companies and why they fit the thesis.

ClutchLead
Creator/SMB marketplace backing an early team at pre‑seed; aligns with the firm’s focus on people over product and consumer‑focused bets.
Empromptu AILead
Enterprise AI infrastructure at the earliest stage; matches the generalist thesis of backing strong technical founders.
Xella HealthLead
Women’s precision‑health platform combining diagnostics and AI; fits the firm’s early digital‑health bets.
PlayMaker SoftwareLead
Vertical SaaS for sponsorship operations; classic early B2B product in a niche market, aligning with a software focus.
Grw AILead
AI‑driven B2B SaaS for sales coaching; early‑stage enterprise software with strong founder‑market fit.
ApprovedLead
Fintech infrastructure for mortgages from repeat operators; co‑led first institutional check consistent with the firm’s “first round” approach.
Carrot Fertility
Digital‑health benefits leader; notable early support of a category‑defining company.
The Athletic
Consumer subscription media that later achieved a high‑profile exit; early investor in a landmark media startup.
Pair Eyewear
Consumer/DTC eyewear brand with product innovation and strong brand; Precursor participated as part of an early syndicate.
Incredible Health
Healthcare labor marketplace that scaled into later rounds; early participation fits the firm’s health‑tech interest.

Key people

Partners who lead investments and shape the thesis.

CH
Charles Hudson
Managing Partner & Founder
consumerhealthcare/digital healthenterprise/SaaSfintech/paymentse-commerce/marketplacesmedia/entertainment
AJ
Ashtan Jordan
Principal
consumerenterprise SaaSearly-stage
MG
Marina Girgis
Principal
enterprise SaaSAIearly-stage
MF
Mia Farnham
Principal
consumerearly-stage

Public voice

Notable statements and public positions.

“We invest in early-stage companies headquartered in North America… We typically invest up to $500,000 in Pre‑Seed and Seed rounds up to $5 million… We make 30‑40 new investments per year on average.” – Precursor Ventures, Philosophy page.
“We invest in pre‑seed and seed rounds of $5 million or less… When we invest, we typically will invest up to $500K. We are happy to lead rounds of $1M or less, but we do not need to be the lead investor.” – Precursor Ventures, Investment Criteria (Notion).
“Your fund size, for the most part, dictates your check size, ownership targets, and portfolio construction.” – Charles Hudson, “Fund Size Is Still Strategy” (Substack, Apr 26 2023).